Compare UNIT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNIT | OCS |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 60 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2024 | N/A |
| Metric | UNIT | OCS |
|---|---|---|
| Price | $12.57 | $11.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $8.88 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.1M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 660.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,234,500,000.00 | N/A |
| Revenue This Year | $65.59 | $466.06 |
| Revenue Next Year | $1.95 | $479.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.49 | N/A |
| 52 Week Low | $4.18 | $10.52 |
| 52 Week High | $12.65 | $34.48 |
| Indicator | UNIT | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 69.58 | 22.05 |
| Support Level | $10.71 | N/A |
| Resistance Level | N/A | $21.00 |
| Average True Range (ATR) | 0.41 | 1.91 |
| MACD | 0.07 | -1.27 |
| Stochastic Oscillator | 100.00 | 2.59 |
Uniti is the product of the August 2025 merger of the firm with Windstream, its former primary customer. The combined firm owns a 240,000 route-mile fiber network that serves enterprise and residential customers. Selling high-capacity fiber circuits to enterprises generates about 20% of consolidated revenue. Uniti's residential networks reach about 4.5 million households, mostly in less-populated markets in the Southeast, but only about 1.9 million of these locations have been upgraded with fiber. Legacy copper-cable networks serve the remainder. Residential services account for about a third of total revenue. Small business and wholesale services provided within this residential service territory account for about 20% of revenue.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.